SUPLEXA
08 Jun 2021
Trial Summary
A Phase 1, First-in-Human, Open-label, Single-Arm study of SUPLEXA™ therapy in Patients with Metastatic Solid Tumors and Haematologic Malignancies
Acronym:
SUPLEXA
ACTRN/NCT /ethics:
NCT05237206
Scientific title:
Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies
Sponsor / Cooperative group:
Alloplex Biotherapeutics Inc
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Metastatic or Widespread |
| Anticipated Start Date | 2022-03-08 |
| Anticipated End Date | 2024-03-08 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | A/Prof Rohit Joshi |
| Recruitment Status | Recruiting |
| Hospital | Southern Oncology Clinical Research Unit |
|---|---|
| Clinical Trial Coordinator | Meggan O'Riley |
| Meggan.ORiley@socru.org.au | |
| Phone | 0491 679 039 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Recruiting |